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Summary objectves To report on the cumulative proportion of deaths occurring within 3 months of starting
antiretroviral treatment (ART) and to identify factors associated with such deaths, among adults at
primary health centres in a rural district of Malawi.
methods Retrospective cohort study: from June 2006 to April 2008, deaths occurring over a 3-month
period were determined and risk factors examined.
results A total of 2316 adults (706 men and 1610 women; median age 35 years) were included in the
analysis and followed up for a total of 1588 person-years (PY); 277 (12%) people died, of whom 206
(74%) people died within 3 months of initiating ART (cumulative incidence: 13.0; 95% conﬁdence
interval: 11.3–14.8 per 100 PY of follow-up). Signiﬁcant risk factors associated with early deaths
included male sex, WHO stage 4 disease, oesophageal or persistent oral candidiasis and unexplained
presumed or measured weight loss >10%. One in every 3 patients who either died or was lost to follow
up had unexplained weight loss >10%, and survival in this group was signiﬁcantly different from
patients without this condition.
conclusions Seven of 10 patients who die after initiating ART at primary health centres die early.
Speciﬁc groups of patients are at higher risk of such mortality and should receive priority attention,
care and support.
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Introduction
Antiretroviral treatment (ART) dramatically improves the
survival of patients living with HIV⁄AIDS (Egger et al.
2002; Mocroft et al. 1998). In Malawi, a resource-limited
country in Southern Africa, ambitious plans to scale-up
ART country-wide began in early 2004. By the end of
December 2007, 141 449 patients had been placed on
treatment from 163 public health facilities (NAC 2007;
Lowrance et al. 2008).
Reports from second and third line hospital facilities in
Malawi and other developing countries show that despite
providing ART, between 8% and 26% of patients die
within the ﬁrst year of initiating ART (Coetzee et al. 2004;
Braitstein et al. 2006; Zachariah et al. 2006a; Lawn et al.
2008) with most deaths occurring during the ﬁrst few
months.
In order to improve geographical equity and ART access
for the rural poor, the current focus in Malawi (as in many
other sub-Saharan African countries) is to decentralise
ART delivery to the level of peripheral health centres (the
primary care level) (Zachariah et al. 2006b; Deribe et al.
2008). Very early mortality, namely deaths occurring
within 3 months of starting ART, at the health centre level
in such resource-limited settings with potential limitations
in human resource capacity and clinical acumen
(WHO 2006a; Philips et al. 2008) has not yet been
described.
We conducted a retrospective analysis among adults
initiated on ART at primary health centres in a rural
district of Malawi, in order to report on the cumulative
proportion of deaths occurring within 3 months of starting
ART, and to identify risk factors associated with such
deaths.
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Study setting and population
This study was conducted in Thyolo, the largest rural
district in Malawi with about 600 000 inhabitants. The
inhabitants of Thyolo are principally subsistence farmers,
earning less than 4 USD per week. Eighty percent of all
income comes through daily labour in tea and coffee
plantations.
The district has one main public hospital and nine
primary health centres, seven of which progressively
started to deliver ART services from June 2006. All ART
naı ¨ve adults starting ART at health centres between 1st
June 2006 and 29th April 2008 were included in this
analysis.
All staff involved with ART delivery undertake a
standardised national training course, and ART delivery
sites require formal accreditation from the Ministry of
Health. At health centre level, ART delivery is managed by
a medical assistant, one nurse, a clerk and a receptionist.
Initial on-the-job training was conducted, in which a
supervising doctor or a senior clinician was actively
involved with ART initiations at each health centre.
A mobile district team with an experienced clinician
(a clinical ofﬁcer) provides ongoing monthly support and
monitoring of health centres. A community network of
home-based care volunteers and community nurses
supported by Me ´decins Sans Frontie ´re ´s facilitate care and
referrals (Zachariah et al. 2007).
ART eligibility and treatment outcomes
According to the National guidelines, all HIV-positive
patients presenting in WHO Clinical stage 3 or 4, or with a
CD4 count of <250 cells⁄mm
3 (irrespective of WHO
staging) are eligible for ART (MOHP⁄NAC 2006). CD4
counts were not routinely available at health centres;
however, when a patient presented with a CD4 count
performed either at the hospital or elsewhere, this was
taken into consideration.
At the time of presentation, all patients undergo a
complete medical examination; they are assessed for WHO
Clinical Stages, and treated for opportunistic disease.
Patients assessed as being eligible for ART undergo group
and individual counselling sessions and are educated on
HIV infection and the implications of therapy. Once
started on treatment, patients are reviewed back at the
health centre after 2 weeks and from then at monthly
intervals.
The ﬁrst-line ART regimen in Malawi (MOHP⁄NAC
2006) is a ﬁxed dose combination of Stavudine (d4T),
Lamivudine (3TC) and Nevirapine (NVP) (Triomune
 ). In
case of d4T- and NVP-related side effects, the respective
alternatives are Zidovudine (AZT) and Efavirenz (EFV).
ART is offered free of charge and monitored using
standardised ART treatment master cards and an ART
register (Harries et al. 2004; Libamba et al. 2005). Stan-
dardised treatment outcomes are monitored every month in
the patient master cards, and updated each month in the
ART register. Treatment outcomes are deﬁned as: alive and
on ART, a patient who is alive and on ART at the facility
where he⁄she is registered; died, patient who has died for
any reason while on ART; loss to follow-up (defaulted),
patient placed on ART and not seen at the ART facility for
3 months; stopped, patient who is known to have stopped
treatment for any reason during treatment; transferred out,
patient who is transferred-out permanently to another
treatment facility. A district supervisory team systemati-
cally checks the validity of outcome data monthly and
reports to a national supervisory team that cross-checks
these data independently every quarter.
During the latter part of the study period (from mid
2007 onwards), all patients with moderate malnutrition
(body mass index, BMI: 16–17) received a monthly
nutritional ration (Likuni Phala–corn-soya blend, CSB) of
approximately 1350 kcal⁄day; those with severe mal-
nutrition (BMI <16) received a ration of 2684 kcal⁄day
(CSB and plumpy nut). HIV positive individuals in Thyolo
did not receive isoniazid preventive therapy as this is as yet
not part of national guidelines in Malawi.
Statistical analysis
Treatment outcomes for all patients starting ART from 1st
June 2006 were censored on 30th April 2008. The
cumulative proportion of deaths that occurred at 3 months
(early mortality) was designated as the dependent variable
for identifying potential risk associations. Since Thyolo has
a well-developed network of community volunteers and
nurses who follow up HIV-positive individuals at home,
reliable ascertainment of deaths was possible (Zachariah
et al. 2007). Baseline case registration details and the main
WHO deﬁning opportunistic disease that was recorded at
the time of starting ART were used to compare those who
died and those remaining alive and on ART within 3
months. The 10% cut-off for unexplained severe weight
loss (presumed or measured) was in line with WHO criteria
for weight loss in clinical stage 3 and clinical stage 4 disease
(WHO 2006b). The term ‘unexplained’ means that the
reasons for the weight loss have no explanation within the
routine healthcare system, and that the aetiology of the
weight loss is unclear. As baseline weight was unavailable
for all patients, diagnosis of this condition was based purely
on self reporting by the patient who on speciﬁc questioning
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body weight. This is therefore a subjective (presumed)
interpretation, and the case deﬁnition is purely clinical. The
measures of risk were determined by crude odds ratios
(ORs) and adjusted odds ratios (adjusted ORs). The ORs
were adjusted using multivariate logistic regression and all
related P-values are based on the Walds test. Variables with
scarce data were excluded from the initial multivariate
model and a stepwise backward elimination method. As we
were unsure of the reliability of baseline weight that was
recorded during the entire study period, we preferred not to
include this variable in the regression model.
Differences between groups were compared using the v
2
test for categorical variables and the Wilcoxon rank-sum
test. The v
2 test for trend was used to test for linear trends.
Survival estimates were determined using the Kaplan–
Maier method and compared using the Cox–Mantel (log-
rank) test. The level of signiﬁcance was set at P = 0.05 or
less, and 95% conﬁdence intervals (CIs) were used
throughout. Data analysis was performed using the STATA
8.2 software (Stata corporation, Texas 77845, USA).
Ethical approval
General measures are provided in the Thyolo district ART
facilities to ensure patient conﬁdentiality, consent for HIV
testing, and counselling and support for those who receive
a positive HIV test result. The data in this study did not
include patient identiﬁers. The Malawi National Health
Science Research Committee provides general oversight
and approval for the collection and use of routine
programmatic data for monitoring and evaluation, and
does not require a formal submission for ethical approval
for the type of study conducted in this paper.
Results
Characteristics of the study population and treatment
outcomes
Of a total of 4088 individuals receiving ART at the health
centre level, 1772 patients were excluded from the analysis;
1688 had initiated ART at the hospital level and were
transferred into the health centre and 84 were children
aged less than 15 years. The remaining 2316 adults (aged
15 years or more) who had initiated ART at health centres
were included in the study. These comprised 706 (30%)
men and 1610 women (median age: 35 years, interquartile
range (IQR): 29–42 years). The majority of patients were
subsistence farmers (76%).
At ART initiation, 18 were in WHO stage 2 with a CD4
count of under 250 cells⁄mm
3, 2003 (87%) were in WHO
stage 3 and 295 (13%) were in WHO stage 4. All patients
were placed on a ﬁrst-line ART regimen; 2312 (99.8%)
were started on a regimen of D4T⁄3TC⁄NVP while four
patients received an alternative ﬁrst-line regimen
(AZT⁄3TC⁄NVP).
Treatment outcomes censured on 30th April 2008 were:
1868 (81%) alive and on ART, 277 (12%) deaths, 109
(5%) lost to follow up, 57 (2%) transferred out and 5
stopped ART (0.2%). Data on exact cause(s) of death were
not available.
Incidence, risk factors for early deaths and differences in
survival between groups
Patients were followed up for a total period of 1588
person-years (PY) (mean: 8.2 months, IQR: 2.6–12.2
months) during which time there were 277 ascertained
deaths (cumulative incidence per 100 PY of follow up:
17.5, 95% CI: 15.5–19.6 PY). Of the 277 deaths, 206
(74%) occurred during the ﬁrst 3 months of initiating ART
(cumulative incidence: 13.0, 95% CI: 11.3–14.8 PY).
Figure 1 shows the cumulative incidence of death while on
ART at health centres. Table 1 compares basic case
registration details and the main baseline opportunistic
disease diagnosed pre-ART among those who died within 3
months of initiating ART when compared with those who
remained alive and on ART during the same period.
Signiﬁcantly higher proportions of males, patients in WHO
stage 4, patients with oesophageal candidiasis and patients
with unexplained presumed or measured weight loss of
>10% died (Table 1). Over half of all early deaths were
associated with unexplained presumed or measured weight
loss >10% and persistent oral candida (Table 1). In the
multivariate model, signiﬁcant risk factors associated with
early deaths included male sex, WHO stage 4 disease,
oesophageal or persistent oral candidiasis and unexplained
presumed or measured weight loss >10% (Table 2). A
linear trend for death was observed in relation to WHO
stage (v
2 for trend = 12.35; P < 0.001).
Figure 2 shows the signiﬁcant difference in Kaplan–
Meier survival probability in patients with and without
unexplained weight loss >10%. Survival probability was
also signiﬁcantly different with regard to WHO stage (log-
rank test v
2 = 17.9; P < 0.001) and sex (log-rank test
v
2 = 19.4: P < 0.001) (Figures not shown).
During the ﬁrst 3 months, 10 (0.4%) patients were
declared lost to follow-up and this may include concealed
deaths. Patients lost to follow-up were ﬁve males and ﬁve
females, eight patients in WHO stage 3 and two in WHO
stage 4. Their baseline opportunistic diseases comprised
three with unexplained weight loss, one with oral candida,
four with severe bacterial infections and two with active
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robust statistical comparisons with those who died or
remained alive. Since these numbers are few, they are also
unlikely to signiﬁcantly change the reported incidence rate
of early mortality.
Discussion
This is one of the ﬁrst studies reporting on early deaths
among a relatively large cohort of patients initiated on
ART at health centre level in a sub-Saharan African
country where >7 of every 10 declared deaths occurred
within the ﬁrst 3 months of starting treatment. Signiﬁcant
risk factors associated with such very early mortality
included male sex, WHO stage 4 disease, presumed or
measured weight loss >10% and oesophageal or persistent
oral candida. With many sub-Saharan African countries
like Malawi embarking on decentralisation of ART to
peripheral health facilities (WHO 2006c) the ﬁndings of
this analysis raise a number of issues.
First, there was a higher proportion of deaths in males
than females, which may be due to men seeking medical
care at a more advanced stage of immunodeﬁciency and
being less compliant with therapy (ART-LINC 2006). This
issue needs to be more actively addressed through targeted
information and education sessions as well as targeted
counselling.
Second, although the overall death rate of 12% reported
in this study is comparable with other hospital-based data
from sub-Saharan Africa (Lawn et al. 2005) and Thyolo
(Zachariah et al. 2006a) and might be deemed acceptable,
reducing overall mortality and particularly early mortality
is still vital to improve overall programme outcomes and to
raise the credibility of the ART programme from the
perspective of the beneﬁciaries, health workers and com-
munity at large. There are several possible reasons for early
mortality in patients starting ART, including delayed
presentation of patients and thus advanced HIV⁄AIDS
disease, delayed diagnosis, undiagnosed opportunistic
infections and life-threatening HIV-related complications
such as anaemia, bacteraemia and TB preceding or during
ART, and delays in ART initiation at the health facility.
Unrecognised drug-related side effects, drug interactions
and immune reconstitution inﬂammatory syndrome (IRIS)
may also contribute to this problem. High early mortality
rates among patients on ART mirror mortality rates in the
period preceding ART and are likely to reﬂect patient
status at programme enrolment and the quality of preced-
ing healthcare (Lucas et al. 1994; Lawn et al. 2006, 2008).
Possible approaches to address these challenges have been
discussed before (Lawn et al. 2006, 2008; Zachariah et al.
2006a).
Third, patients with unexplained presumed or measured
weight loss of over 10%, and those with recurrent oral or
oesophageal candidiasis constituted 6 of 10 deaths at
health centres, and these patients had a signiﬁcantly higher
risk of dying in the ﬁrst 3 months of starting ART.
Unexplained weight loss may be a proxy for malnutrition,
which by further compromising host immunity and
predisposing to life-threatening nutritional deﬁciencies and
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Intensive nutritional rehabilitation and use of micro-
nutrients to improve cell mediated and humoral immunity
might be beneﬁcial. Health centre have begun to provide a
Ready to Use Therapeutic Food (RUTF) such as the
‘plumpy nut’ (Wikipedia 2008); which is easy to store,
requires no preparation or special supervision, and may be
an easily deployable strategy. There may also be a relation
between weight loss and undiagnosed TB which could
present in an atypical or occult manner. In a study from
northern Malawi, 77% of patients who developed TB after
starting ART had unexplained weight loss >10% before
starting ART, an observation that concurs with this
hypothesis (Yu et al. 2008). Patients with weight loss
should therefore undergo intensiﬁed screening for TB
which includes at the very least systematic questioning
about cough for more than 2 weeks and a sputum
examination for anyone with cough for over 2 weeks.
Although sputum cultures, chest X-rays (WHO 2006c) and
an abdominal ultrasound for glands are desirable, the
necessary equipment is not available at peripheral health
centre level. Facilitating patient referral to the district
hospital such as organising transport on a scheduled basis
or paying transport fees may improve the uptake of such
investigations. There is evidence from sub-Saharan Africa
that often, the only indication of TB might be a positive
blood culture. Operational research to determine the
prevalence of undiagnosed TB in such patients would thus
Table 1 Characteristics of patients who
died and remained alive in the ﬁrst three
months of starting antiretroviral treatment
(ART), at health centres, Thyolo, Malawi
Variable
Died Alive
P-value* n (%) n (%)
Total 206 (9.0) 2083 (91.0) –
Sex
Females 122 (59) 1472 (71)
Males 84 (41) 611 (29) 0.001
Age (years)
£35 years 85 (41) 918 (44) 0.45
>35 years 121 (59) 1166 (56)
Age, years, median (IQR) 34 (28–41) 35 (29–42) 0.43
WHO clinical stage
Stage I or II with CD4 <250 cells⁄ll 0 18 (1) 0.18
Stage III 164 (80) 1816 (87) 0.002
Stage IV 42 (20) 249 (12) 0.001
Main opportunistic infection at ART start
Oesophageal candidiasis 9 (4) 44 (2) 0.04
Kaposi sarcoma 12 (6) 69 (3) 0.06
Cryptococcal meningitis 2 (1) 5 (0.2) 0.07
Persistent oral candida 43 (21) 380 (18) 0.35
Unexplained chronic diarrhoea >1 month 22 (11) 238 (11) 0.75
Unexplained persistent fever >1 month 0 (0) 11 (0.5) 0.5
Unexplained presumed weight loss >10% 72 (35) 543 (26) 0.001
Pneumocystics jeroveci pneumonia 1 (0.5) 3 (0.1) 0.3
Recurrent severe bacterial pneumonia 15 (7) 250 (12) 0.03
Active tuberculosis 15 (7) 181 (9) 0.5
Severe bacterial infection 12 (6) 187 (9) 0.13
Others: Anaemia, skin conditions,
herpes simplex, toxoplasmosis
2 (1) 56 (3) 0.12
Low CD4 count⁄no active opportunistic
infection on ART start
1 (0.5) 116 (6) 0.001
Duration on ART (months) [Median (IQR)] 1 (0.5–1.6) 253 (8.3–12.6) –
WHO, World Health Organization; ART, antiretroviral treatment; TB, tuberculosis; IQR,
interquartile range.
*v
2 test for categorical variables and Wilcoxon rank-sum rank-sum test for continuous
variables.
Pneumonia, empyema, pyomyosities, meningitis, suspected bacteremia⁄septicaemia, bone
or joint infection.
A CD4 cell count of <250 cells⁄mm
3 irrespective of WHO clinical stage.
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Lewis et al. 2002; Peters et al. 2004). This issue also
highlights the need for access to simpler and more efﬁcient
point of care TB diagnostic tools for resource-limited
settings. Patients with unexplained weight loss >10%
may also have occult lethal bacteraemias, e.g. from
Streptococcus pneumoniae and non-typhoidal Salmonella
(Gilks et al. 1990; McCarthy 1992) and blood culture
studies would also be useful to determine the relative
contribution of these pathogens.
This is the ﬁrst report of an association between
recurrent oral or oesophageal candidiasis and death at
health centres. We believe that a considerable proportion
of individuals diagnosed with oral recurrent candida might
also have oesophageal candida. Under-diagnosis of the
oesophageal candida is likely at primary health centres
with busy health workers not systematically asking about
symptoms originating in the oesophagus, such as from
epigastric pain, heart burn and particularly difﬁculty in
swallowing. Deﬁnitive diagnosis of oesophageal candidia-
sis requires endoscopy, which is inaccessible for patients at
the health centre level; patients with oral candidiasis who
remain untreated before starting on ART or who face
delays in being initiated on ART undergo immune
deterioration with subsequent colonisation and spread of
candida into the oesophagus. For these reasons
Table 2 Risk factors associated with very
early deaths (during ﬁrst three months)
in health centres, Thyolo, Malawi (n-2145) Variables
Very early
deaths (%) OR* Adjusted OR P
Gender
Female 122⁄1594 (7.7) 1
Male 84⁄695 (12.1) 1.6 (1.2–2.2) 1.6 (1.2–2.1) 0.003
Age (years)
£35 years 85⁄1002 (8.5) 1 –
>35 years 122⁄1287 (9.4) 1.1 (0.8–1.5)
WHO Stage
Stage II 0⁄18 (0) –
Stage III 164⁄1980 (8.3) 1
Stage IV 42⁄291 (14.4) 1.9 (1.3–2.7) 1.7 (1.2–2.4) 0.006
Unexplained weight loss
>10% 134⁄1674 (8.0) 1
Absent 72⁄615 (11.7) 1.5 (1.1–2.1) 1.7 (1.2–2.4) 0.001
Present
Oesophageal⁄persistent oral candida
Absent 154⁄1813 (8.5) 1
Present 52⁄476 (10.9) 1.3 (0.9–1.8) 1.7 (1.1–2.4) 0.007
Kaposi sarcoma
Absent 194⁄2208 (8.8) 1
Present 12⁄81 (14.8) 1.8 (1.0–3.4)
Unexplained chronic diarrhoea
Absent 184⁄2029 (9.1) 1
Present 22⁄260 (8.5) 1.1 (0.7–1.7)
Active tuberculosis
Absent 191⁄2093 (9.1) 1
Present 15⁄196 (7.7) 0.8 (0.5–1.4)
Severe bacterial infections§
Absent 194⁄2090 (9.3) 1 –
Present 12⁄199 (6.0) 0.6 (0.3–1.1)
Recurrent bacterial pneumonia
Absent 191⁄2024 (9.4) 1
Present 15⁄265 (5.7) 0.6 (0.3–1.0)
WHO, World Health Organization.
*OR, odds ratio; 95% conﬁdence intervals in parenthesis.
Adjusted using multivariate logistic regression. Adjusted odds ratios of variables that
showed statistical signiﬁcance are presented; 95% conﬁdence intervals in parenthesis.
v
2 for trend = 12.35 P £ 0.001.
§Pneumonia, empyema, pyomyosities, meningitis, suspected bacteremia⁄septicaemia, bone
or joint infection.
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diagnosis of recurrent oral candida may have had a much
more severe condition than assessed clinically and are thus
at high risk of death (Connolly 1989; Morgan 2000).
We thus considered it rational from an operational
perspective to combine persistent oral candidiasis and
oesophageal candidiasis as a single variable in the regres-
sion model. The real reasons underlying death in such
patients are unclear but there are a number of possibilities.
First, difﬁculty or the inability to swallow has a profound
effect on quality of life, often resulting in reduced nutri-
tional intake, malnutrition and weight loss. This is espe-
cially so if treatment-seeking is delayed, as is often the case
with poor people. Thus, even if oral and oesophageal
conditions alone may not be life threatening initially, these
sequelae would tend to weaken patients and make it more
difﬁcult to survive other AIDS-related complications.
Second, patients may be treated for oral recurrent candi-
diasis with nystatin or gentian violet paint, treatments with
very low cure rates for oesophageal candidiasis (Ravera
et al. 1999). Third, herpes simplex virus (HSV), cytomeg-
alovirus (CMV) and idiopathic HIV-related oesophagitis
may co-exist with oesophageal candidiasis and be missed
or left untreated (Ayisi et al. 1997). Azole resistance can
also be a problem in our setting, where repeated courses of
azole treatment are used for relapsing fungal infections,
especially oral recurrent candida (Wilcox et al. 1996;
Dromer et al. 1997). There might also have been drug
stock interruptions at the health centre. Finally, appropri-
ate palliative and supportive care to relieve symptoms and
related complications (e.g. inability to swallow) is virtually
non-existent at health centres. But without this, patients
may be unable to take their cotrimoxazole prophylaxis,
prophylaxis for other opportunistic infections and ART,
leading to a worsening of prognosis. All these issues merit
further evaluation.
In the meantime, systematically assessing all patients for
symptoms of oesophageal candida is justiﬁed with the use
of sequential empiric therapy as an initial approach if
symptoms are present. This would ﬁrst involve a 14-day
trial of ﬂuconazole (USDHH 2003) and if response is
unsatisfactory, a subsequent empiric course of acyclovir for
HSV which is readily available and well-tolerated. The
next in sequence would be an empiric course of IV
ganciclovir for suspected CMV. However, this treatment is
expensive, has signiﬁcant side effects, is not readily
available in many settings and many clinical teams have
little experience administering it. Finally, if aphthous ulcers
are present in the mouth, a trial course of corticosteroids
for idiopathic oesophagitis would be appropriate (accom-
panied with an antifungal as steroids can worsen fungal
infections).
Patients must also be given priority for initiating ART in
order to hasten immune restitution, and those who cannot
swallow must be offered supportive care and particularly
pain relief (Chen et al. 2008). Alternative formulations for
buccal, rectal and sublingual administration would make
drug administration easier and enhance compliance in
patients who cannot swallow.
The strengths of this study were that a large number of
patients were included, outcomes were reliably ascertained
using master cards and registers that are robust and
regularly checked by supervision teams and as the data
come from a program setting the ﬁndings probably reﬂect
the operational reality on the ground. Deaths were also
reliably ascertained and only 10 patients were declared lost
to follow-up during the ﬁrst 3 months. Although some of
these patients may have died, with reports on this outcome
not getting back to clinic staff, this is unlikely to have
affected the overall results.
The limitations of the study are that (i) CD4 counts were
not performed at health centres and we were thus unable to
compare the degree of immunodeﬁciency between the
groups; (ii) height was not systematically recorded and thus
we are unable to report on BMI, (iii) weight loss was
presumed weight loss (by the patient) and thus subjective;
(iv) laboratory tests, in particular liver enzymes (ALAT),
were not available and thus we do not know the contri-
bution of conditions such as fatal liver toxicities; (v) as
oesophageal candidiasis is associated with lower CD4 cell
counts, and low CD4 counts have been consistently
associated with ART-related mortality, the omission of
baseline CD4 counts in the model could have resulted in
residual confounding.
This study shows that speciﬁc groups of patients initiated
on ART at health centres are at higher risk of early
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support. The ﬁndings from this study highlight the urgent
need to address the issue of high early case fatality in
patients at primary level through relevant interventions and
operational research while waiting for the results of
randomised controlled trials. Some of these are being
planned while others are already under way, and the results
may better deﬁne the precise reasons for early mortality
and better inform on disease-speciﬁc prevention and
treatment interventions to reduce such mortality.
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